StockData
Z Squared Inc. logo

Z Squared Inc. (ZSQR) company profile

ZSQRNasdaqFinance ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 8/30
$2.19+0.25 (+12.63%)

Close on Nov 18, 2026Market cap $115.81MP/E –Yield –

About Z Squared

Finance Services, SIC 6199

Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical and technology company structured across two main divisions. Its biopharmaceutical division develops cell therapy platforms, including natural killer cell therapies, chimeric antigen receptor technologies, and diagnostic tools designed for cancer, autoimmune conditions, and infectious diseases. Its technology division provides artificial intelligence marketing software and robotic process automation tools to optimize enterprise workflows. The company directs its healthcare solutions toward patients suffering from hematologic malignancies and viral infections, while its technology services cater to corporate clients seeking advertising campaigns and digital webinar solutions.

The company is headquartered in Wexford, Pennsylvania, and operates as a Delaware corporation following its initial incorporation in the British Virgin Islands. Business activities are conducted through several operating subsidiaries, including majority-owned SNAP Biosciences and GEAR Therapeutics, as well as wholly owned pharmaceutical units. Its clinical development pipeline includes two Phase 1 trial programs.

Summary of the business section of Z Squared's latest annual report, written by StockData.

Company profile

Company

Legal name
Z Squared Inc.
Founded
2018
Headquarters
Fort Lauderdale, FL
Address
550 South Andrews Ave., Ste #700 33301
Phone
(954) 400-9994
Employees
6, Dec 31, 2025
Industry
Finance Services
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Astra Audit and Advisory LLC, Tampa, Florida

Stock & identifiers

Ticker
ZSQR
Former tickers
COEP until Apr 28, 2026; BHSE until Nov 3, 2022
Exchange
Nasdaq
IPO date
Nov 2, 2020
Shares outstanding
53M, Aug 11, 2026
Public float
$28.23M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
13-for-1, Aug 13, 2026; 1-for-20 reverse, Dec 31, 2024
SEC CIK
1759186
CUSIP
98878K108
ISIN
US98878K1088
FIGI
BBG00XTTT1C5
Share class FIGI
BBG00XTTT1D4
LEI
5299004UXP8XTVR4KR35
EIN
98-1465952

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David Elias HalabuChief Executive Officer, Director1,464,905
Michelle Ellen BurkeCo-Chief Executive Officer, Director16,447
Daniel Alexander YeraceVP Operations, Director70,531
David MehalickCEO and President, Director330,192
Christopher Ryan SchadelChief Marketing Officer6,636
Brian CogleyChief Financial Officer30,724
Jeffery Keeslar HarrisChief Technology Officer12,444
Christine Elise SheehyVP Compliance and Secy64,031
Kenneth Lyle CooperDirector1,644
Bryan Eric FuerstDirector1,644
Adam Craig SohnDirector1,644
Gene SalkindDirector41,799
Christopher P. CochranDirector8,950
Tara DeSilvaDirector8,950
Chris CaliseDirector2,243,741
Philippe DeschampsDirector8,950

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Nov 2, 2020
Offer price
$10.00
Securities offered
7,500,000
Gross proceeds
$75.00M
Exchange
Nasdaq
First trading day
Dec 17, 2020
First-day close
$9.90-1.0%
Lock-up ends (est.)
Jun 15, 2021

“We are offering 7,500,000 units at an offering price of $10.00 per unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Currently, we have six employees, of which four are full-time employees and two are part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 14, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 30, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 28, 2026Name changeName changed from Coeptis Therapeutics Holdings, Inc. to Z Squared Inc.
Apr 24, 2026DelistingNotice of delisting from exchange (Form 25)
Jan 16, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 26, 2025MergerRegistration of securities for a merger or exchange offer (S-4)
Sep 30, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2024Late filingNotification of late filing
Jul 31, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 1, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 30, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 22, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 9, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 29, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2022Late filingNotification of late filing
Nov 3, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 28, 2022Name changeName changed from Bull Horn Holdings Corp. to Coeptis Therapeutics Holdings, Inc.
Oct 28, 2022DelistingNotice of delisting from exchange (Form 25)
May 25, 2022MergerRegistration of securities for a merger or exchange offer (S-4)
Mar 31, 2022Late filingNotification of late filing
Nov 15, 2021Late filingNotification of late filing
Sep 3, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 16, 2021Late filingNotification of late filing
May 28, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 17, 2021Late filingNotification of late filing
Nov 2, 2020IPOInitial public offering priced (424B4 prospectus)
Oct 27, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?